Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease

George R. Siber, Claudette Thompson, G. Raymond Reid, Janné Almeido-Hill, Bonnie Zacher, Mark Wolff, Mathuram Santosham

Research output: Contribution to journalArticlepeer-review

Abstract

A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by >0.15 µg/ml within 4-6 h and by 2-4 µg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligo-saccharide-diptheria CRM197conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.

Original languageEnglish (US)
Pages (from-to)S129
JournalJournal of Infectious Diseases
Volume165
DOIs
StatePublished - Jun 1992

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease'. Together they form a unique fingerprint.

Cite this